Data From Texas: VCs, Still Mostly Underwater, Ride Stocks As Long As Possible

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

How Are Biotech VC Funds Performing? See Data From Five State Pension Funds
Is Bigger Better in Biotech Venture Capital?
12 VCs Who Matter, But You Never Read About
‘Pharmaphobia’ Pushes Back Against Anti-Industry Crusade, But Comes Up Short